

# Dilan S Athauda

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1722165/publications.pdf>

Version: 2024-02-01

22  
papers

1,172  
citations

623734

14  
h-index

713466

21  
g-index

25  
all docs

25  
docs citations

25  
times ranked

1582  
citing authors

#	ARTICLE	IF	CITATIONS
1	Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2017, 390, 1664-1675.	13.7	527
2	Diabetes medications and risk of Parkinson's disease: a cohort study of patients with diabetes. <i>Brain</i> , 2020, 143, 3067-3076.	7.6	108
3	Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease. <i>Neuropharmacology</i> , 2018, 136, 260-270.	4.1	68
4	Nanosopic Characterisation of Individual Endogenous Protein Aggregates in Human Neuronal Cells. <i>ChemBioChem</i> , 2018, 19, 2033-2038.	2.6	52
5	Technologies Assessing Limb Bradykinesia in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2017, 7, 65-77.	2.8	50
6	What Effects Might Exenatide have on Non-Motor Symptoms in Parkinson's Disease: A Post Hoc Analysis. <i>Journal of Parkinson's Disease</i> , 2018, 8, 247-258.	2.8	47
7	GBA-Associated Parkinson's Disease: Progression in a Deep Brain Stimulation Cohort. <i>Journal of Parkinson's Disease</i> , 2017, 7, 635-644.	2.8	44
8	Post hoc analysis of the Exenatide-PD trial: Factors that predict response. <i>European Journal of Neuroscience</i> , 2019, 49, 410-421.	2.6	43
9	Amyloid processing in COVID-19-associated neurological syndromes. <i>Journal of Neurochemistry</i> , 2022, 161, 146-157.	3.9	35
10	Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson's disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The Exenatide-PD3 study. <i>BMJ Open</i> , 2021, 11, e047993.	1.9	32
11	The Impact of Type 2 Diabetes in Parkinson's Disease. <i>Movement Disorders</i> , 2022, 37, 1612-1623.	3.9	30
12	Proximity extension assay testing reveals novel diagnostic biomarkers of atypical parkinsonian syndromes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 768-773.	1.9	29
13	Repurposing anti-diabetic drugs for the treatment of Parkinson's disease: Rationale and clinical experience. <i>Progress in Brain Research</i> , 2020, 252, 493-523.	1.4	26
14	The Bradykinesia Akinesia Incoordination (BRAIN) Tap Test: Capturing the Sequence Effect. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 462-469.	1.5	23
15	Diabetes, BMI, and Parkinson's. <i>Movement Disorders</i> , 2020, 35, 201-203.	3.9	14
16	Multiphasic acute disseminated encephalomyelitis (ADEM) following influenza type A (swine specific) Tj ETQq0 0 0,rgBT /Overlock 10 Tf	3.8	13
17	Combining biomarkers for prognostic modelling of Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 707-715.	1.9	9
18	The Future of Incretin-Based Approaches for Neurodegenerative Diseases in Older Adults: Which to Choose? A Review of their Potential Efficacy and Suitability. <i>Drugs and Aging</i> , 2021, 38, 355-373.	2.7	8

#	ARTICLE	IF	CITATIONS
19	Cerebral air embolism during endoscopic retrograde cholangiopancreatography: treatment with therapeutic hypothermia. <i>Endoscopy</i> , 2014, 46, E151-E152.	1.8	7
20	High Grade Glioma Mimicking Voltage Gated Potassium Channel Complex Associated Antibody Limbic Encephalitis. <i>Case Reports in Neurological Medicine</i> , 2014, 2014, 1-4.	0.4	6
21	A restless night's sleep. <i>BMJ: British Medical Journal</i> , 2012, 344, d8347-d8347.	2.3	1
22	Evolving Infarction in the Anterior Circulation. <i>New England Journal of Medicine</i> , 2014, 371, e20.	27.0	0